Expect Repatha and Praluent to Be Saved as Add-On Meds for High Cholesterol

May 2017

You'll hear buzz about using the "PCSK9 inhibitors," Repatha (evolocumab) and Praluent (alirocumab), in patients with heart disease.

New evidence suggests that adding the cholesterol med Repatha to a statin in patients with heart disease and other risks (diabetes, etc) prevents future cardiovascular events.

But don't expect to see a lot of patients get PCSK9 inhibitors.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

IV Medications Handle Overfill Properly to Ensure Patients Receive Correct Doses
Practice Loop in Your Pharmacist at the Right Times to Keep Patients Safe
Diuretics Help Improve Safety With Diuretic Meds
Sepsis Be Ready to Prep IV Vitamin C Doses for Sepsis Patients
Vaccines Watch for Confusing Abbreviations With Vaccines
Acetaminophen Look for Changes in Children's Chewable Acetaminophen Strengths
HIV & AIDS Use Strategies to Reduce Med Errors in HIV Patients
Pediatrics Doses for Neonatal Abstinence Syndrome Meds Will Be Increased, Then Reduced
Cholesterol Expect Repatha and Praluent to Be Saved as Add-On Meds for High Cholesterol
Overactive Bladder Expect to See More Extended-Release Meds Used for Overactive Bladder

Expect Repatha and Praluent to Be Saved as Add-On Meds for High Cholesterol

Practical advice for a better career, with unlimited access to CE

Table of Contents